ClinicalTrials.Veeva

Menu

Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis (RELIABLE)

D

Don Carlo Gnocchi Onlus Foundation

Status

Enrolling

Conditions

Multiple Sclerosis, Relapsing-Remitting

Treatments

Other: personalized combined physical and cognitive intervention

Study type

Interventional

Funder types

Other

Identifiers

NCT06303024
RELIABLE Clinical Study

Details and patient eligibility

About

Our project proposal is based on an individualized rehabilitation approach in patients with early stage relapsing remission (RR) MS. This approach will be based on risk stratification obtained using several clinical and demographic parameters that are not commonly used in clinical practice. This risk score will be obtained from an extensive neuropsychological, psychosocial and physical assessment to which patients will undergo at baseline and at one-year follow-up.The risk score will allow a better stratification of patients' risk of disease worsening/progression and the application of a preventive and personalized strategy.

Full description

This is a multicentric no-profit pilot study, composed by two phases. The objective of the first phase is to create a multi-factorial assessment and prognostic profiling into different risk categories, integrating different techniques in a common evaluation approach. MS patients, referred to the MS Centers of Careggi University Hospital and the Sheba Medical Centre in Tel-Aviv, will be recruit and assess at baseline and 12-months follow-up using a comprehensive approach. The patients will undergo an advanced motor performance evaluation, neuropsychological assessment, and a brain MRI scan to evaluate the presence of new/enlarging T2 lesions, new gadolinium-positive lesions, and volumetric analyses (e.g., total brain volume, grey matter volume, white matter volume, T2 lesions volume, normalized thalamic and hippocampal volume). Data collected from the comprehensive baseline and 12 months assessment will be used to generate a risk score for disease worsening in the short-term, classifying the patients into low/mild, moderate, or high risk. All the variables significantly associated with disease activity will be combined in the risk score.The objectives of II Phase are to apply the previously obtained risk score on a novel cohort using the same inclusion/exclusion criteria; to evaluate the impact of a combined rehabilitation approach in reducing the proportion of patients with disease activity.The risk score obtained from follow-up data of the test cohort applied to the newly recruited patients. Only patients with moderate to high risk of worsening in this new cohort will be included in the rehabilitation program. The included patients will receive an innovative and personalized rehabilitation approach, including counselling on lifestyle habits, an aerobic moderate to high-intensity physical training and a computerized cognitive rehabilitation program.The efficacy of the rehabilitation approach will be then evaluated by comparing patients included in this cohort with patients in the same risk groups included in the phase 1 cohort. Across Phases of the study, Uppsala University partner, will conduct a surveillance and will consider Social and ethical aspects of the integrated rehabilitation approach. Personalized preventive interventions and tailored risk information may raise pressing ethical issues that need careful reflection.

Enrollment

140 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosis of RRMS based on the 2017 McDonald criteria;
  • age ≥ 18 years;
  • EDSS ≤ 2.0;
  • disease duration ≤ 5 years;
  • verification of MS subtype,
  • duration of disease and EDSS will be accomplished by obtaining a signed consent form for the release of medical information from the treating neurologist.

Exclusion criteria

  • history of relevant psychiatric comorbidities.
  • Severely depressed subjects assessed through the Beck Depression Inventory (scores ≥ 29);
  • relapses or corticosteroid treatment in the 30 days before inclusion;
  • history of substance abuse;
  • presence of non-MS related physical or cognitive impairment that could make the patient unable to complete the study assessments.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

140 participants in 1 patient group

personalized combined physical and cognitive intervention
Experimental group
Description:
The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload, combined with a computer based cognitive rehabilitation program carried out twice a week for 12 weeks, using the Rehacom software.
Treatment:
Other: personalized combined physical and cognitive intervention

Trial contacts and locations

1

Loading...

Central trial contact

Claudia Niccolai, PSY; Maria Pia Amato, Prof

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems